Comparing EQ-5D-3L and EQ-5D-5L in Measuring the HRQoL Burden of 4 Health Conditions in China

Overview

Journal Eur J Health Econ

Specialty Health Services

Date 2022 May 10

PMID 35538178

Authors

Guizhi Weng

Yanming Hong

Nan Luo

Clara Mukuria

Jie Jiang

Zhihao Yang

Sha Li

Affiliations

Soon will be listed here.

Abstract

Background: EQ-5D-3L has been used in the National Health Services Survey of China since 2008 to monitor population health. The five-level version of EQ-5D was developed, but there lacks evidence to support the use of five-level version of EQ-5D in China. This study was conducted to compare the measurement properties of both the EQ-5D-3L and EQ-5D-5L in quantifying health-related quality of life (HRQoL) burden for 4 different health conditions in China.

Methods: Participants from China were recruited to complete the 3L and 5L questionnaire via Internet. Quota was set to recruit five groups of individuals, with one group of individuals without any health condition and one group of generalized anxiety disorder (GAD), HIV/AIDS, chronic Hepatitis B (CHB), or depression, respectively. The 3L and 5L were compared in terms of response distributions, percentages of reporting 'no problems', index value distributions, known-group validity and their relative efficiency.

Results: In total, 500 individuals completed the online survey, including 140 healthy individuals, 122 individuals with hepatitis B, 107 with depression, 90 individuals with GAD and 101 with HIV/AIDS. 5L also had smoother and less clustered index value distributions. Healthy group showed different response distributions to the four condition groups. The percentage of reporting 'no problems' decreased significantly in the 5L in all domains (P < 0.01), especially in the pain/discomfort dimension (relative difference: 43.10%). Relative efficiency suggested that 5L had a higher absolute discriminatory power than the 3L version between healthy participant and the other 4 condition groups, especially for the HIV/AIDS group when the 3L results was not significant.

Conclusions: The 5L version may be preferable to the 3L, as it demonstrated superior performance with respect to higher sensitivity to mild health problems, better relative efficiency and responses and index value distributions.

Citing Articles

Effects of chronic diseases on health related quality of life is mediated by sleep difficulty in middle aged and older adults.

Wu Y, Chen Z, Cheng Z, Yu Z, Qin K, Jiang C Sci Rep. 2025; 15(1):2987.

PMID: 39849013 PMC: 11758026. DOI: 10.1038/s41598-025-86420-1.

Evaluating health-related quality of life in Ethiopia: systematic review and meta-analysis of EQ-5D-based studies.

Tarekegn T, Gebrie D, Kassaw A, Dagne Taye A, Girmaw F, Ashagrie G Front Epidemiol. 2024; 4:1455822.

PMID: 39553423 PMC: 11563791. DOI: 10.3389/fepid.2024.1455822.

The effect of positive mental well-being on patient reported outcome (PRO): finding from a cross-sectional multi-disease study in China.

Yang Z, Luo N, Hong Y Health Qual Life Outcomes. 2024; 22(1):100.

PMID: 39550577 PMC: 11568534. DOI: 10.1186/s12955-024-02314-2.

Cross-cultural adaptation and validation for central sensitization inventory: based on Chinese patients undergoing total knee arthroplasty for knee osteoarthritis.

Xu C, Yao S, Wei W, Zhang H, Ma J, Shang L J Orthop Surg Res. 2023; 18(1):960.

PMID: 38093300 PMC: 10717624. DOI: 10.1186/s13018-023-04375-3.

Measurement of Health-Related Quality of Life in Individuals With Rare Diseases in China: Nation-Wide Online Survey.

Xu R, Ng S, Luo N, Dong D, Zhang S JMIR Public Health Surveill. 2023; 9:e50147.

PMID: 37906229 PMC: 10646671. DOI: 10.2196/50147.

References

Devlin N, Brooks R . EQ-5D and the EuroQol Group: Past, Present and Future. Appl Health Econ Health Policy. 2017; 15(2):127-137. PMC: 5343080. DOI: 10.1007/s40258-017-0310-5. View

Devlin N, Krabbe P . The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ. 2013; 14 Suppl 1:S1-3. PMC: 3728454. DOI: 10.1007/s10198-013-0502-3. View

Janssen M, Pickard A, Golicki D, Gudex C, Niewada M, Scalone L . Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2012; 22(7):1717-27. PMC: 3764313. DOI: 10.1007/s11136-012-0322-4. View

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10):1727-36. PMC: 3220807. DOI: 10.1007/s11136-011-9903-x. View

Cheung P, Wong C, Samartzis D, Luk K, Lam C, Cheung K . Psychometric validation of the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) in Chinese patients with adolescent idiopathic scoliosis. Scoliosis Spinal Disord. 2016; 11:19. PMC: 4973368. DOI: 10.1186/s13013-016-0083-x. View

Wang S, Wu B, Zhu L, Leng L, Bucala R, Lu L . Construct and criterion validity of the Euro Qol-5D in patients with systemic lupus erythematosus. PLoS One. 2014; 9(6):e98883. PMC: 4043925. DOI: 10.1371/journal.pone.0098883. View

Tsang H, Cheung J, Wong C, Cheung P, Lau C, Chung H . Psychometric validation of the EuroQoL 5-dimension (EQ-5D) questionnaire in patients with spondyloarthritis. Arthritis Res Ther. 2019; 21(1):41. PMC: 6354427. DOI: 10.1186/s13075-019-1826-x. View

Xu R, Dong D, Luo N, Wong E, Wu Y, Yu S . Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia. Eur J Health Econ. 2021; 22(4):547-557. DOI: 10.1007/s10198-021-01273-5. View

Zhu J, Yan X, Liu C, Wang H, Wang L, Cao S . Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing. Qual Life Res. 2020; 30(3):841-854. DOI: 10.1007/s11136-020-02636-w. View

10.

Jia Y, Cui F, Li L, Zhang D, Zhang G, Wang F . Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res. 2014; 23(8):2355-63. DOI: 10.1007/s11136-014-0670-3. View

11.

Zeng X, Sui M, Liu B, Yang H, Liu R, Tan R . Measurement Properties of the EQ-5D-5L and EQ-5D-3L in Six Commonly Diagnosed Cancers. Patient. 2020; 14(2):209-222. DOI: 10.1007/s40271-020-00466-z. View

12.

You R, Liu J, Yang Z, Pan C, Ma Q, Luo N . Comparing the performance of the EQ-5D-3 L and the EQ-5D-5 L in an elderly Chinese population. Health Qual Life Outcomes. 2020; 18(1):97. PMC: 7147057. DOI: 10.1186/s12955-020-01324-0. View

13.

Yu H, Zeng X, Sui M, Liu R, Tan R, Yang J . A head-to-head comparison of measurement properties of the EQ-5D-3L and EQ-5D-5L in acute myeloid leukemia patients. Qual Life Res. 2020; 30(3):855-866. DOI: 10.1007/s11136-020-02644-w. View

14.

Jiang J, Hong Y, Zhang T, Yang Z, Lin T, Liang Z . Comparing the measurement properties of the EQ-5D-5L and the EQ-5D-3L in hypertensive patients living in rural China. Qual Life Res. 2021; 30(7):2045-2060. DOI: 10.1007/s11136-021-02786-5. View

15.

Pan C, Sun H, Wang X, Ma Q, Xu Y, Luo N . The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Qual Life Res. 2014; 24(7):1767-74. DOI: 10.1007/s11136-014-0902-6. View

16.

Tsang H, Wong C, Cheung P, Lau C, Chung H, Cheung J . Responsiveness of the EuroQoL 5-Dimension (EQ-5D) questionnaire in patients with spondyloarthritis. BMC Musculoskelet Disord. 2021; 22(1):439. PMC: 8122540. DOI: 10.1186/s12891-021-04315-4. View

17.

Cheung P, Wong C, Lau S, Cheung J . Responsiveness of the EuroQoL 5-dimension (EQ-5D) in adolescent idiopathic scoliosis. Eur Spine J. 2017; 27(2):278-285. DOI: 10.1007/s00586-017-5330-1. View

18.

Fang H, Farooq U, Wang D, Yu F, Younus M, Guo X . Reliability and validity of the EQ-5D-3L for Kashin-Beck disease in China. Springerplus. 2016; 5(1):1924. PMC: 5099307. DOI: 10.1186/s40064-016-3613-3. View

19.

Li L, Liu C, Cai X, Yu H, Zeng X, Sui M . Validity and reliability of the EQ-5D-5 L in family caregivers of leukemia patients. BMC Cancer. 2019; 19(1):522. PMC: 6543556. DOI: 10.1186/s12885-019-5721-2. View

20.

Yang F, Jiang S, He X, Li H, Wu H, Zhang T . Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative Study. Pharmacoecon Open. 2020; 5(1):101-109. PMC: 7895880. DOI: 10.1007/s41669-020-00212-z. View